Neurobiology of Aging
Volume 31, Issue 4 , Pages 578-590 , April 2010

Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain

  • J.E. Simpson

      Affiliations

    • Academic Unit of Pathology, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    • ,
  • P.G. Ince

      Affiliations

    • Academic Unit of Pathology, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    • ,
  • G. Lace

      Affiliations

    • Academic Unit of Pathology, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    • ,
  • G. Forster

      Affiliations

    • Academic Unit of Pathology, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    • ,
  • P.J. Shaw

      Affiliations

    • Academic Unit of Neurology, University of Sheffield Medical School, Sheffield S10 2RX, UK
    • ,
  • F. Matthews

      Affiliations

    • MRC Biostatistics Unit, Institute of Public Health, University of Cambridge, Cambridge, UK
    • ,
  • G. Savva

      Affiliations

    • MRC Biostatistics Unit, Institute of Public Health, University of Cambridge, Cambridge, UK
    • ,
  • C. Brayne

      Affiliations

    • Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge, UK
    • ,
  • S.B. Wharton

      Affiliations

    • Academic Unit of Pathology, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 114 226 1342; fax: +44 114 226 1464.
    • ,
  • on behalf of the MRC Cognitive Function and Ageing Neuropathology Study Group

Received 7 December 2007 ,Revised 29 February 2008 ,Accepted 18 May 2008.

References 

  1. Armstrong RA. Laminar distribution of beta-amyloid deposits in dementia with Lewy bodies and in Alzheimer's disease. Am. J. Alzheimers Dis. Other Dement. 2006;21(3):175–181
  2. Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology. 1992;42(9):1681–1688
  3. Beach TG, McGeer EG. Lamina-specific arrangement of astrocytic gliosis and senile plaques in Alzheimer's disease visual cortex. Brain Res. 1988;463(2):357–361
  4. Beach TG, Walker R, McGeer EG. Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia. 1989;2(6):420–436
  5. Beckstrom H, Julsrud L, Haugeto O, Dewar D, Graham DI, Lehre KP, et al. Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's disease. J. Neurosci. Res. 1999;55(2):218–229
  6. Bhattacharyya A, Oppenheim RW, Prevette D, Moore BW, Brackenbury R, Ratner N. S100 is present in developing chicken neurons and Schwann cells and promotes motor neuron survival in vivo. J. Neurobiol. 1992;23(4):451–466
  7. Boston-Howes W, Gibb SL, Williams EO, Pasinelli P, Brown RH, Trotti D. Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J. Biol. Chem. 2006;281(20):14076–14084
  8. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389–404
  9. Brayne C, McCracken C, Matthews FE. Cohort profile: the Medical Research Council Cognitive Function and Ageing Study (CFAS). Int. J. Epidemiol. 2006;35(5):1140–1145
  10. Crols R, Saerens J, Noppe M, Lowenthal A. Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome. J. Neurol. 1986;233(3):157–160
  11. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology. 1988;38(11):1682–1687
  12. Danbolt NC. Glutamate uptake. Prog. Neurobiol. 2001;65(1):1–105
  13. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J. Neuropathol. Exp. Neurol. 1999;58(4):376–388
  14. Duffy PE, Rapport M, Graf L. Glial fibrillary acidic protein and Alzheimer-type senile dementia. Neurology. 1980;30(7 Pt 1):778–782
  15. Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 2002;9(3):305–318
  16. Fernando MS, Ince PG. Vascular pathologies and cognition in a population-based cohort of elderly people. J. Neurol. Sci. 2004;226(1/2):13–17
  17. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, et al. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke. 2006;37(6):1391–1398
  18. Fukuyama R, Izumoto T, Fushiki S. The cerebrospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer's disease patients and correlates with severity of dementia. Eur. Neurol. 2001;46(1):35–38
  19. Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia. Neurosci. Lett. 1997;235(1/2):5–8
  20. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1989;86(19):7611–7615
  21. Hansen LA, Armstrong DM, Terry RD. An immunohistochemical quantification of fibrous astrocytes in the aging human cerebral cortex. Neurobiol. Aging. 1987;8(1):1–6
  22. Harrison PJ, Heath PR, Eastwood SL, Burnet PW, McDonald B, Pearson RC. The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins. Neurosci. Lett. 1995;200(3):151–154
  23. Harrison PJ, Kleinman JE. Methodological Issues. In:  Harrison PJ,  Roberts GW editor. The neuropathology of schizophrenia. Progress and interpretation. Oxford: Oxford University Press; 2000;p. 339–350
  24. Hilbig H, Bidmon HJ, Oppermann OT, Remmerbach T. Influence of post-mortem delay and storage temperature on the immunohistochemical detection of antigens in the CNS of mice. Exp. Toxicol. Pathol. 2004;56(3):159–171
  25. Kashon ML, Ross GW, O’Callaghan JP, Miller DB, Petrovitch H, Burchfiel CM, et al. Associations of cortical astrogliosis with cognitive performance and dementia status. J. Alzheimers Dis. 2004;6(6):595–604discussion 73–81
  26. Le Prince G, Delaere P, Fages C, Duyckaerts C, Hauw JJ, Tardy M. Alterations of glial fibrillary acidic protein mRNA level in the aging brain and in senile dementia of the Alzheimer type. Neurosci. Lett. 1993;151(1):71–73
  27. Li S, Mallory M, Alford M, Tanaka S, Masliah E. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J. Neuropathol. Exp. Neurol. 1997;56(8):901–911
  28. Mancardi GL, Liwnicz BH, Mandybur TI. Fibrous astrocytes in Alzheimer's disease and senile dementia of Alzheimer's type. Acta Neuropathol. 1983;61(1):76–80
  29. Maragakis NJ, Rothstein JD. Mechanisms of Disease: astrocytes in neurodegenerative disease. Nat. Clin. Pract. Neurol. 2006;2(12):679–689
  30. Marshak DR, Pesce SA, Stanley LC, Griffin WS. Increased S100 beta neurotrophic activity in Alzheimer's disease temporal lobe. Neurobiol. Aging. 1992;13(1):1–7
  31. Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann. Neurol. 1996;40(5):759–766
  32. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 1995;21(2):195–218
  33. Meda L, Baron P, Scarlato G. Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins. Neurobiol. Aging. 2001;22(6):885–893
  34. Morgan TE, Rozovsky I, Goldsmith SK, Stone DJ, Yoshida T, Finch CE. Increased transcription of the astrocyte gene GFAP during middle-age is attenuated by food restriction: implications for the role of oxidative stress. Free Rad. Biol. Med. 1997;23(3):524–528
  35. Mrak RE, Griffin WS. Glia and their cytokines in progression of neurodegeneration. Neurobiol. Aging. 2005;26(3):349–354
  36. Mrak RE, Griffin WS. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol. Aging. 2001;22(6):903–908
  37. Mrak RE, Griffinbc WS. The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease. Neurobiol. Aging. 2001;22(6):915–922
  38. Mrak RE, Sheng JG, Griffin WS. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. J. Neuropathol. Exp. Neurol. 1996;55(3):273–279
  39. MRC-CFAS, 1998. Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study. The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Psychol. Med. 28 (2), 319–335.
  40. MRC-CFAS, 2001. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357 (9251), 169–175.
  41. Nagele RG, D’Andrea MR, Lee H, Venkataraman V, Wang HY. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 2003;971(2):197–209
  42. Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC, Wegiel J. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol. Aging. 2004;25(5):663–674
  43. Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA. Involvement of oxidative stress in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2006;65(7):631–641
  44. Nunomura A, Honda K, Takeda A, Hirai K, Zhu X, Smith MA, et al. Oxidative damage to RNA in neurodegenerative diseases. J. Biomed. Biotechnol. 2006;2006(3):82323
  45. Overmyer M, Helisalmi S, Soininen H, Laakso M, Riekkinen P, Alafuzoff I. Astrogliosis and the ApoE genotype. An immunohistochemical study of postmortem human brain tissue. Dement. Geriatr. Cogn. Disord. 1999;10(4):252–257
  46. Pertusa M, Garcia-Matas S, Rodriguez-Farre E, Sanfeliu C, Cristofol R. Astrocytes aged in vitro show a decreased neuroprotective capacity. J. Neurochem. 2007;101(3):794–805
  47. Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem. Int. 2001;39(5–6):409–413
  48. Petzold A, Jenkins R, Watt HC, Green AJ, Thompson EJ, Keir G, et al. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. Neurosci. Lett. 2003;336(3):167–170
  49. Rossner S, Lange-Dohna C, Zeitschel U, Perez-Polo JR. Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme. J. Neurochem. 2005;92(2):226–234
  50. Sastre M, Klockgether T, Heneka MT. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int. J. Dev. Neurosci. 2006;24(2–3):167–176
  51. Segovia G, Porras A, Del Arco A, Mora F. Glutamatergic neurotransmission in aging: a critical perspective. Mech. Ageing Dev. 2001;122(1):1–29
  52. Selinfreund RH, Barger SW, Pledger WJ, Van Eldik LJ. Neurotrophic protein S100 beta stimulates glial cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 1991;88(9):3554–3558
  53. Sheng JG, Mrak RE, Griffin WS. S100 beta protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques. J. Neurosci. Res. 1994;39(4):398–404
  54. Sheng JG, Mrak RE, Rovnaghi CR, Kozlowska E, Van Eldik LJ, Griffin WS. Human brain S100 beta and S100 beta mRNA expression increases with age: pathogenic implications for Alzheimer's disease. Neurobiol. Aging. 1996;17(3):359–363
  55. Steiner J, Bernstein HG, Bielau H, Berndt A, Brisch R, Mawrin C, et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci. 2007;8:2
  56. Unger JW. Glial reaction in aging and Alzheimer's disease. Microsc. Res. Tech. 1998;43(1):24–28
  57. Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol. Aging. 2003;24(2):321–331
  58. Wadiche JI, Arriza JL, Amara SG, Kavanaugh MP. Kinetics of a human glutamate transporter. Neuron. 1995;14(5):1019–1027
  59. Wallin A, Blennow K, Rosengren LE. Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia. Dementia. 1996;7(5):267–272
  60. Westphalen RI, Scott HL, Dodd PR. Synaptic vesicle transport and synaptic membrane transporter sites in excitatory amino acid nerve terminals in Alzheimer disease. J. Neural. Transm. 2003;110(9):1013–1027
  61. Williams SM, Sullivan RK, Scott HL, Finkelstein DI, Colditz PB, Lingwood BE, et al. Glial glutamate transporter expression patterns in brains from multiple mammalian species. Glia. 2005;49(4):520–541
  62. Wu Y, Zhang AQ, Yew DT. Age related changes of various markers of astrocytes in senescence-accelerated mice hippocampus. Neurochem. Int. 2005;46(7):565–574
  63. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med. 2003;9(4):453–457

PII: S0197-4580(08)00170-X

doi: 10.1016/j.neurobiolaging.2008.05.015

Neurobiology of Aging
Volume 31, Issue 4 , Pages 578-590 , April 2010

Article Tools

* Image Usage & Resolution